Neurocrine Biosciences Inc (NBIX)
Neurocrine Biosciences Inc (NBIX) is a biopharmaceutical company focused on the development and commercialization of treatments for neurological and endocrine disorders. Founded in 1992, the company specializes in innovative therapies for conditions such as Parkinson's disease, Tourette syndrome, and endometriosis, leveraging expertise in neuroscience and endocrine biology.
Company News
Nxera Pharma reported increased revenues from PIVLAZ® and QUVIVIQ® in Japan, progress in partnered programs including Neurocrine's Phase 3 trial, and launched a new proprietary pipeline targeting obesity and weight management.
Neurocrine Biosciences reported strong Q2 2025 financial results, with revenue of $687.5 million, exceeding analyst expectations. The company saw significant growth from INGREZZA and a successful launch of CRENESSITY, while continuing to invest in its drug pipeline and research and development.
Neurocrine Biosciences has amended its agreement with Takeda Pharmaceutical to obtain exclusive global rights to develop and commercialize the depression drug osavampator, except in Japan where Takeda will reacquire exclusive rights.
Sector ETF report for PBE